Core Viewpoint - The company reported a significant decline in both revenue and net profit for 2025, indicating challenges in demand and increased competition in the market [4][5]. Financial Performance - In 2025, the company achieved a revenue of 2.45 billion yuan, down 18.9% year-on-year, and a net profit of 1.29 billion yuan, down 34.1% year-on-year [4]. - Quarterly breakdown for 2025 shows revenues of 660 million, 640 million, 570 million, and 590 million yuan for Q1 to Q4, with year-on-year declines of 17.9%, 25.1%, 21.3%, and 9.6% respectively [4]. - Net profits for the same quarters were 440 million, 350 million, 300 million, and 200 million yuan, with declines of 15.9%, 41.7%, 34.6%, and 46.9% respectively [4]. Product Performance - Revenue from solution products and gel products in 2025 was 1.26 billion and 890 million yuan, down 27.5% and 26.8% year-on-year respectively [5]. - Sales volumes for these products were 512,300 and 69,600 units, reflecting declines of 19.3% and 22.1% year-on-year [5]. - Average prices for solution and gel products were 247 yuan and 1,277 yuan per unit, down 10.2% and 6.1% year-on-year respectively [5]. Profitability and Cost Structure - The company's gross margin decreased by 1.9 percentage points to 92.7% in 2025, while the net profit margin fell by 12.1 percentage points to 52.6% [6]. - In Q4 2025, the gross margin was 90.6%, down 3.4 percentage points year-on-year, and the net profit margin was 33.7%, down 23.6 percentage points year-on-year [6]. - The increase in expense ratio by 16.0 percentage points to 38.2% was noted, with sales, management, R&D, and financial expense ratios rising significantly [7]. Strategic Developments - The company has made significant strides in the regenerative and botulinum toxin markets, including the acquisition of REGEN Biotech, Inc. and the launch of new products [8]. - The introduction of the "Hutox" botulinum toxin product is expected to enhance revenue, with projected annual contributions of up to 600 million yuan based on a 90% gross margin [8]. - The diversification of product offerings is anticipated to strengthen the company's market position and profitability through synergistic effects [8].

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Insights - The company reported a revenue of 2.45 billion yuan in 2025, a year-on-year decrease of 18.9%, and a net profit attributable to shareholders of 1.29 billion yuan, down 34.1% year-on-year [5] - The decline in performance is attributed to weak demand and increased competition, although the revenue drop in Q4 2025 has narrowed [6] - The company has made significant progress in the regenerative and botulinum toxin sectors, enhancing its product portfolio and market position [9] - Despite short-term challenges, the company has a robust pipeline of new products and is expected to benefit from the introduction of new offerings [10] Financial Performance Summary - In 2025, the company's revenue by product category was 1.26 billion yuan for solution products and 0.89 billion yuan for gel products, with respective year-on-year declines of 27.5% and 26.8% [6] - The gross margin decreased by 1.9 percentage points to 92.7%, while the net profit margin fell by 12.1 percentage points to 52.6% [7] - The company’s operating expenses increased by 16.0 percentage points to 38.2% in 2025, driven by higher sales and management costs [8] Product Development and Market Position - The company has diversified its product offerings, successfully acquiring REGEN Biotech, Inc. and launching new products in the regenerative and botulinum toxin categories [9] - The approval of the botulinum toxin product Hutox® is expected to contribute significantly to revenue, with potential annual sales of up to 600 million yuan [9] - The company’s strategy to enhance its product mix and leverage existing distribution channels is anticipated to strengthen its competitive edge [10] Earnings Forecast - The report projects a slight decrease in net profit forecasts for 2026 and 2027 to 1.45 billion yuan and 1.68 billion yuan, respectively, with an introduction of a new forecast for 2028 at 2.13 billion yuan [10] - The expected earnings per share (EPS) for 2026, 2027, and 2028 are 4.78 yuan, 5.56 yuan, and 7.04 yuan, respectively [10]

Core Insights - The Chinese medical beauty market is experiencing a significant transformation in 2025, marked by a notable divergence in the performance of various brands within the regenerative filling materials sector, with "Zhenai Su Fei" leading with a 463% growth while "Yiyan Shi" saw a 56% decline [1][2] - The market is witnessing a "Matthew Effect," where leading brands are consolidating their positions, while smaller brands struggle to survive [1][10] Regenerative Filling Materials - Regenerative filling materials have become the "MVP" of the year, with a 93.40% increase in sales in 2025, continuing a three-year growth trend [2] - "Zhenai Su Fei" from Aimeike achieved the highest growth rate at 463%, while "Yiyan Shi" faced a significant decline of 56% [2][3] - The performance of "Yiyan Shi" is attributed to its early market entry, but its novelty has worn off, leading to decreased consumer interest [3] Market Dynamics - The market is increasingly competitive, with new brands and materials entering, but consumers tend to prefer established brands for their reliability [4] - The sales of the once-popular ultrasonic device have dropped significantly, with a 55.2% decline in 2025, as consumers are opting for newer products and are more budget-conscious [4][5] Equipment and Technology - The "Meila Meisu" ultrasonic knife has emerged as a leading anti-aging device, with a 147.22% increase in sales, appealing to users over 35 seeking non-invasive treatments [4][5] - The ultrasonic device is transitioning from a "market dividend period" to a "technical barrier period," indicating a shift in competitive dynamics [5][7] Hyaluronic Acid - Hyaluronic acid remains a top-selling product, with a 19.70% increase in sales in 2025, maintaining its status as a staple in the market [8] - Despite its growth, hyaluronic acid faces challenges such as market oversupply and price wars, which could weaken its position in the long term [8][9] Future Growth Areas - The market is shifting towards specialized treatments, with a focus on individual needs and the emergence of new segments like collagen reorganization and hair loss treatment, which are expected to see significant growth [10][11] - The collagen reorganization market is projected to grow at a compound annual growth rate of 41.4% from 2023 to 2027, indicating strong potential [10]

Core Insights - The Chinese medical beauty market is experiencing a significant shift in 2025, marked by a 93.40% growth in the regenerative filling materials sector, but with notable disparities among brands [1][2] - The "Matthew Effect" is becoming evident, where leading brands are gaining market share at the expense of smaller competitors, particularly in the context of regulatory barriers and technological advancements [1][10] Regenerative Filling Materials - Regenerative filling materials have emerged as the "MVP" of the year, with a 93.40% increase in sales in 2025, continuing a trend of rapid growth over the past three years [2] - The brand "Zhenai Su Fei" under Aimeike leads with a remarkable 463% growth, while "Yiyan Shi" from Huadong Pharmaceutical, once a market leader, has seen a 56% decline [2][3] - Despite the growth of "Zhenai Su Fei," its contribution to Aimeike's overall performance remains uncertain, as the company reported over a 20% decline in revenue and net profit in the first three quarters of 2025 [2] Market Dynamics - The decline of "Yiyan Shi" is attributed to its earlier market entry leading to reduced novelty among consumers, and some users seeking alternative products after initial experiences [3] - The market for ultrasonic devices, once a star in anti-aging treatments, has seen a 55.2% drop in sales, indicating a shift in consumer preferences and budget constraints [4][8] - In contrast, the "Meila Meisheng" ultrasonic knife has gained popularity, with a 147.22% increase in sales, appealing to users aged 35 and above [4][5] Competitive Landscape - The competitive landscape is tightening, with head brands further squeezing the market space for smaller brands, as consumers tend to prefer established, reliable products [4] - The decline in ultrasonic device sales is not solely due to the emergence of new technologies but also reflects market misuse and consumer fatigue [7][10] Hyaluronic Acid Market - Hyaluronic acid remains a top-selling product, with a 19.70% increase in sales in 2025, despite facing challenges such as oversupply and intense price competition [8][9] - The product's versatility and ability to cater to a wide range of consumer needs contribute to its sustained popularity, positioning it as a mainstay in the anti-aging market [9] Future Growth Areas - The market is transitioning towards specialized segments, with a focus on individual needs and the emergence of new growth areas such as recombinant collagen products, hair loss treatments, and weight management [10][11] - The recombinant collagen market is projected to grow at a compound annual growth rate of 41.4% from 2023 to 2027, indicating strong potential for expansion [10]

Group 1 - The company has completed the acquisition of a controlling stake in REGEN, with the domestic product "Zhen Ai Su Fei" already launched for sale, and attention is on the sales ramp-up during the transition period [1] - The company has received approval for Minoxidil topical solution, and it is expected that 2026 will see a concentrated launch of new pipelines such as botulinum toxin, with a focus on the progress of these new products in the domestic market [1] - The company has completed its first cosmetic raw material filing, with the core ingredient "Glycyrrhetinic Acid A" sourced from the Chinese herb licorice, which can be used as a skin protectant and moisturizer in cosmetics [1] Group 2 - The traditional product segment is under short-term pressure due to low market sentiment and intensified competition, with Q3 revenue expected to continue its downward trend [2] - For the first three quarters of 2025, revenue was 1.865 billion, down 21.49%, and net profit attributable to the parent company was 1.093 billion, down 31.05% [2] - In Q3 2025, revenue was 566 million, down 21.27%, and net profit attributable to the parent company was 304 million, down 34.61% [2] Group 3 - The company’s performance remains under pressure due to low industry sentiment and increased competition, with a focus on the sales ramp-up of "Zhen Ai Su Fei" during the transition period [3] - The new REGEN factory in South Korea has successfully commenced production, expected to release incremental capacity this year and expand into markets in the Middle East and Southeast Asia [3] - The company is anticipated to experience a concentrated launch of new pipelines in 2026, with attention on the progress of these new products and their market release rhythm [3]

Core Insights - Shenzhen Pengai Medical Aesthetic Hospital celebrated its 20th anniversary, coinciding with the 45th anniversary of the Shenzhen Special Economic Zone, highlighting its growth alongside the city's development [1][2] - The hospital aims to continue advocating for "three regulations, safe beauty" and to enhance its medical technology and service details, focusing on lifecycle management of aesthetic services [1] - The "Shangxing Aesthetics" project was launched in collaboration with Aimeike, emphasizing a positive spirit and cultural significance beyond mere external beauty [2] Company Development - The celebration included participation from over 40 supply chain enterprises, showcasing Pengai's resource integration capabilities within the medical aesthetics industry [2] - The hospital's general manager, Pan Yousheng, reflected on the growth from inception to becoming a regional benchmark, emphasizing a commitment to safety and quality in aesthetic services [1][2] - A recognition ceremony was held for employees with over 15 years of service, underscoring the company's appreciation for long-term dedication [2] Future Strategy - Pengai Hospital views its 20th anniversary as both a milestone and a new starting point, pledging to drive progress in the Chinese medical aesthetics industry with a focus on customer-centricity and technological support [2] - The company aims to collaborate with excellent partners to create a more brilliant future in the next twenty years [2]

Group 1 - The ongoing dispute over the "AestheFill" product involves Aimei Ke's subsidiary REGEN Biotech, which has been restricted from selling the product in mainland China until arbitration is resolved [1][2] - Aimei Ke confirmed that the recent decision is a procedural matter and does not constitute a final arbitration ruling, indicating that REGEN may still sell AestheFill in mainland China [2][3] - The product AestheFill has been out of stock for two months, affecting downstream medical beauty institutions, although Aimei Ke attributes the shortage to distributor sales strategies [2][3] Group 2 - AestheFill has been rebranded as "Zhen Ai Su Fei," but many institutions still refer to it as "Ai Su Fei," leading to confusion in the market [2][3] - There is a significant price discrepancy between the two names, with "Ai Su Fei" priced as low as 8,700 yuan per 200mg unit, while "Zhen Ai Su Fei" is priced around 21,000 yuan for the same quantity [3] - The ability of Aimei Ke to stabilize the sales and pricing of AestheFill remains uncertain and will require further observation [3]

Core Insights - The company's H1 2025 performance fell short of expectations, with revenue of 1.299 billion yuan, down 21.6%, and net profit attributable to shareholders of 789 million yuan, down 29.6% [1] - The Q2 2025 results also showed a decline, with revenue of 636 million yuan, down 25.1%, and net profit attributable to shareholders of 346 million yuan, down 41.8% [2] Financial Performance - H1 2025 revenue breakdown: - Solution revenue: 744 million yuan, down 23.8% - Gel revenue: 493 million yuan, down 23.99% - Lyophilized powder revenue: 19 million yuan - Facial embedding line revenue: 3.32 million yuan, down 4.6% - Other main business revenue: 39 million yuan, up 38.9% [3] - H1 2025 gross margin: 93.44%, down 1.5 percentage points, with declines in gross margins for solution, gel, facial embedding line, and other main businesses [3] - H1 2025 expense ratios: - Sales expense ratio: 11.1%, up 2.6 percentage points - Management expense ratio: 5.34%, up 1.3 percentage points - R&D expense ratio: 12.05%, up 4.5 percentage points - H1 2025 net profit margin: 60.77%, down 6.9 percentage points, and adjusted net profit margin: 55.6%, down 10.2 percentage points [3] Pipeline Progress - The product AestheFill has been renamed "Zhen Ai Su Fei" and officially launched in the Chinese market, with ongoing efforts in team building, channel expansion, and packaging optimization [4] - The company is collaborating with REGEN to expand globally, with an initial focus on increasing market share in South Korea [4] - Regulatory updates include submissions for botulinum toxin and minoxidil lotion, currently under review, and new product registrations for other treatments [4] - Clinical trials are ongoing for several products, with the second-generation embedding line expected to enter registration by 2025 [4] Investment Outlook - The company is expected to face short-term pressure on performance due to low industry sentiment and intensified competition in Q2 [4] - The introduction of a low-threshold light medical beauty chain model by a competitor may stimulate industry demand, with the company positioned to benefit as a leading player [4] - With the adjustment of distribution rights and the gradual rollout of its own pipeline, the company anticipates a concentrated launch period for new products like botulinum toxin in 2026, projecting net profits of 1.6 billion yuan and 2 billion yuan for 2025 and 2026, respectively, corresponding to PE ratios of approximately 38x and 29x [4]

Group 1 - The arbitration regarding the agency rights of AestheFill in mainland China has seen a significant development, with the emergency arbitrator rejecting the request from Datou Medical to revoke the exclusive authorization of Lizhen (Xiamen) Medical Technology Co., Ltd. as the agent [1] - The emergency arbitrator confirmed that REGEN Biotech, Inc. must continue supplying AestheFill products to Datou Medical and cannot deny its status as the exclusive distributor [1] - The decision aims to balance the interests of both parties while ensuring a stable supply of AestheFill products in the Chinese market, minimizing the impact of the dispute on the end market and consumers [1] Group 2 - Despite the ongoing arbitration, the legal status of Lizhen (Xiamen) as the exclusive agent for AestheFill in mainland China remains intact, potentially weakening Datou Medical's claims of illegal deprivation of exclusive distribution rights [2] - REGEN's main reason for seeking to terminate the cooperation agreement with Datou Medical is the latter's transfer of agency business to its controlling shareholder, which violates the exclusivity agreement [2] - The product AestheFill has been renamed to "Zhenai Suofei" and continues to be supplied normally, indicating that the arbitration dispute has not materially affected sales [2] Group 3 - *ST Suwu is facing multiple delisting risks, including false reporting of revenue and profits, which could lead to mandatory delisting due to significant violations [3] - The stock price of *ST Suwu has repeatedly fallen below 1 yuan, putting it at risk of delisting due to its low market value [3] - The company is also dealing with major operational and governance risks, including unresolved large fund occupation issues by its controlling shareholder and ongoing litigation regarding exclusive agency agreements for core aesthetic products [3]

Core Viewpoint - *ST Suwu has experienced a significant decline in both revenue and net profit in the first half of 2025, primarily due to a substantial impairment provision for trade receivables, despite high growth in its medical beauty segment. The loss of exclusive distribution rights for its key product, AestheFill, poses a serious challenge for the company's future performance [2][3][7]. Financial Performance - In the first half of 2025, *ST Suwu reported revenue of 636 million yuan, a year-on-year decrease of 27.08% [3]. - The net profit attributable to shareholders was a loss of 44.42 million yuan, a decline of 281.63% compared to the previous year [3]. - The operating cash flow was negative at -885 million yuan, down 680.0% year-on-year [3]. - Basic earnings per share stood at -0.062 yuan [3]. Business Segment Analysis - The pharmaceutical business, as the traditional core segment, generated revenue of 358.10 million yuan, a decline of 53.81% year-on-year [4]. - The medical beauty segment achieved revenue of 268.19 million yuan, a remarkable increase of 234.73% year-on-year [5]. - The gross profit from the pharmaceutical segment was 184.66 million yuan, down 32.09% year-on-year, while the medical beauty segment's gross profit was 220.44 million yuan, up 231.94% year-on-year [5]. Key Product and Market Changes - The exclusive distribution rights for AestheFill were unilaterally terminated by Regen Biotech, which poses a significant risk to *ST Suwu's revenue stream [7]. - The termination was attributed to alleged violations of the distribution agreement and financial misconduct by *ST Suwu [7][8]. - The product AestheFill will be rebranded as "Zhen Ai Su Fei" in the Chinese market, further complicating *ST Suwu's ability to maintain its market position [8]. Stock Market Activity - Despite the declining performance and potential delisting risks, *ST Suwu's stock has seen unusual trading activity, with significant price increases observed in late August 2025 [8][9]. - The stock price fluctuated, with a notable drop of 1.71% and 5.22% on August 28 and 29, respectively, bringing it close to the warning line of 1 yuan [9].